Persbericht: Programma bekend van gebruikersevent GiLab Commit 2019
Amsterdam — 30 augustus 2019 — GitLab, het DevOps platform,... Lees verder →
- Pharming will take control of commercial rights to its product RUCONEST® in all 36 remaining countries - Pharming will pay a total of EUR7.5 million in two tranches for a ...
Lees verderLEIDEN, Netherlands, Oct. 24, 2019 /PRNewswire/ -- Compared with the first nine months of 2018 (on a like-for-like basis): -- Revenues up 26%, operating profit up 38%, ...
Lees verderDelivered 31% increase in revenue, 51% increase in operating profit and 60% increase in net profit year-on-year Delivered 21% increase in revenue, with increases in operating ...
Lees verderLEIDEN, Netherlands, June 11, 2019 /PRNewswire/ -- Pharming Group N.V. ("Pharming" or "the Company") today announces that, following receipt of the Dutch investigating ...
Lees verderLEIDEN, Netherlands, June 5, 2018 /PRNewswire/ -- New forms of administration for RUCONEST(R) for HAE Expansion of rhC1INH clinical development in pre-eclampsia, contrast ...
Lees verderLEIDEN, Netherlands, May 23, 2018 /PRNewswire/ -- Mr. Jaap Blaak, Former Chairman of the Board of Supervisory Directors, retires from the Board Pharming Group N.V. ...
Lees verderLEIDEN, Netherlands, May 17, 2018 /PRNewswire/ -- 93% increase in revenues from product sales and 110% increase in operating profit compared with the First Quarter 2017 ...
Lees verderLEIDEN, Netherlands, January 4, 2018 /PRNewswire/ -- Bondholders convert EUR7.7 million of their remaining bonds into Pharming Shares and cash Further reduction in net debt ...
Lees verderLEIDEN, the Netherlands, September 29, 2017 /PRNewswire/ -- RUCONEST(R) provided clinically meaningful relief of symptoms in children with hereditary angioedema Pharming ...
Lees verderLEIDEN, Netherlands and LUXEMBOURG, September 26, 2017 /PRNewswire/ -- Allows hereditary angioedema (HAE) patients in all countries to gain access to RUCONEST via Medicines ...
Lees verder